Manon C. Spaander

Feb 23, 2024 | ejso.com | Julie Geerts |Manon C. Spaander |Grard AP. Nieuwenhuijzen |Camiel Rosman |Hanneke van Laarhoven |Rob H.A. Verhoeven | +3 more

Background: Perioperative fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) became standard of care in most Western countries after the FLOT4-AIO trial (2019) showed improved survival compared to perioperative anthracycline triplets. The aim of this study is to compare outcomes of FLOT to anthracycline triplets in the Netherlands using real-world population level data.